Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia

BACKGROUND: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins. METHODS: A cost-consequence model was developed to evaluate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clinicoecon Outcomes Res
Glavni autori: Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Elliott, Brian, Briggs, Andrew
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6219311/
https://ncbi.nlm.nih.gov/pubmed/30464563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S177324
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items